By Counterforce Health Team in Strimvelis (autologous CD34+ ADA-SCID gene therapy) —

How Long Does It Take to Get Strimvelis Gene Therapy Approved by Blue Cross Blue Shield in Virginia? Complete Timeline and Appeals Guide

Answer Box: Getting Strimvelis Covered by Blue Cross Blue Shield in Virginia

Strimvelis gene therapy requires prior authorization from Blue Cross Blue Shield (BCBS) in Virginia, with no specific coverage policy for this EU-approved ADA-SCID treatment. Approval depends on demonstrating medical necessity through genetic testing, failed standard treatments, and international coverage benefits. Timeline: 2-15 days for initial PA review, plus potential appeals. First step: Call BCBS member services to verify international coverage and request medical exception forms for Milan-only treatment at SR-TIGET.

Table of Contents

  1. What Affects Approval Timing
  2. Pre-Submission Preparation (0-2 Days)
  3. Submission to Initial Review (1-15 Days)
  4. Additional Information Requests (1-7 Days)
  5. Decision Window and Outcomes
  6. If Denied: Virginia Appeals Process
  7. Timeline Visual and Milestones
  8. Time-Saving Tips
  9. Common Denial Reasons and Solutions
  10. FAQ

What Affects Approval Timing

Several factors influence how quickly Blue Cross Blue Shield Virginia processes Strimvelis gene therapy requests:

Benefit Structure Complexity

  • Medical vs. Pharmacy Benefit: Gene therapies administered at facilities typically fall under medical benefits, requiring different PA pathways than standard pharmacy drugs
  • International Coverage: Most BCBS Virginia plans treat SR-TIGET Milan as out-of-network foreign care, requiring additional authorization layers
  • Plan Type: HMO members may face stricter network requirements than PPO members for international treatment

Clinical Documentation Requirements

  • ADA-SCID Confirmation: Genetic testing showing biallelic pathogenic ADA gene variants plus enzyme activity <1% of normal
  • Treatment History: Documentation of failed or contraindicated standard treatments (HSCT, enzyme replacement therapy)
  • Urgency Level: Expedited reviews available for life-threatening situations
Note: BCBS Virginia (Anthem) processes specialty drug PAs within 2-5 business days for standard requests and 24-72 hours for urgent cases, but international treatment adds complexity.

Pre-Submission Preparation (0-2 Days)

Essential Documentation Checklist

Insurance Verification

  • Call BCBS member services: 1-800-451-0287
  • Verify international coverage benefits (GeoBlue, Global Core)
  • Request medical exception/international authorization forms
  • Confirm HMO vs. PPO network requirements

Clinical Evidence Package

  • Genetic testing results confirming ADA-SCID diagnosis
  • ADA enzyme activity lab results (<1% normal)
  • Immunologic profile (T-B-NK- phenotype)
  • Documentation of failed/contraindicated treatments
  • SR-TIGET treatment plan and cost estimate
  • Physician letter of medical necessity

Provider Information

  • Treating physician NPI and specialty credentials
  • SR-TIGET facility details and authorization status
  • Current ICD-10 codes (D81.3 for ADA-SCID)

Submission to Initial Review (1-15 Days)

BCBS Virginia PA Process

Standard Submission Channels

Initial Review Timeline

  • Non-urgent requests: Up to 15 calendar days per ACA requirements
  • Urgent requests: 72 hours maximum for life-threatening situations
  • Anthem's operational target: 2-5 business days for complete submissions

What Reviewers Check First

  1. Member eligibility and benefit verification
  2. International coverage provisions
  3. Medical necessity criteria alignment
  4. Complete documentation requirements
  5. Network/out-of-network authorization needs
Tip: Submit PA requests electronically through Availity for real-time status tracking and faster processing.

Additional Information Requests (1-7 Days)

When BCBS requests additional information, the review clock typically pauses. Common requests for Strimvelis include:

Clinical Clarifications

  • More detailed genetic testing reports
  • Specialist consultation notes
  • Treatment failure documentation
  • Contraindication evidence for standard therapies

Administrative Requirements

  • Updated cost estimates from SR-TIGET
  • Facility accreditation documentation
  • International billing arrangements
  • Travel and accommodation plans

How to Respond Quickly

  • Monitor Availity portal daily for information requests
  • Respond within 48 hours to avoid delays
  • Provide complete documentation in single submission
  • Follow up via phone if urgent

Decision Window and Outcomes

Typical Approval Outcomes

Full Approval

  • Coverage authorized for SR-TIGET treatment
  • May include travel/accommodation benefits if covered
  • Requires pre-service authorization before travel

Partial Approval

  • Gene therapy covered but not travel expenses
  • May require out-of-network cost-sharing
  • Additional conditions or monitoring requirements

Denial

  • Most common for experimental/investigational classification
  • Lack of in-network alternatives not established
  • International coverage exclusions

Reading Your Determination Letter

Look for specific denial codes and policy references that guide your appeal strategy. BCBS must provide clear rationale and appeal rights information.

If Denied: Virginia Appeals Process

Internal Appeals with BCBS

Level 1: Standard Internal Appeal

  • Deadline: 180 days from denial notice
  • Timeline: 15-30 days for decision
  • Submit to: BCBS Virginia appeals department
  • Include: Additional clinical evidence, peer-reviewed studies, specialist letters

Expedited Internal Appeal

  • When available: Life-threatening situations
  • Timeline: 72 hours for decision
  • Requires: Physician certification of urgency

Virginia External Review Process

After exhausting internal appeals, Virginia's State Corporation Commission Bureau of Insurance provides external review:

Eligibility Requirements

  • Completed BCBS internal appeals process
  • Medical necessity or experimental treatment denial
  • Virginia-issued plan or opted-in self-funded plan

Timeline and Process

  • Filing deadline: 120 days from final internal denial
  • Standard review: 45 days for IRO decision
  • Expedited review: 72 hours for urgent cases
  • Forms: Form 216-A External Review Request

Virginia External Review Success Factors

  • Comprehensive medical evidence
  • Clear documentation of treatment failures
  • Specialist support for medical necessity
  • Evidence that therapy is not experimental
Virginia Advantage: The state allows expedited external review for certain urgent cases without completing all internal appeals first.

Timeline Visual and Milestones

Milestone Standard Timeline Expedited Timeline Key Actions
Pre-submission 1-2 days Same Gather documentation, verify benefits
Initial PA review 2-15 days 24-72 hours BCBS medical review, network verification
Additional info 1-7 days 1-2 days Respond to requests promptly
Decision issued Day after completion Same Review determination letter
Internal appeal 15-30 days 72 hours Submit additional evidence
External review 45 days 72 hours Independent medical review

Total Timeline Range: 3-67 days (standard) or 2-8 days (expedited)

Time-Saving Tips

Portal Optimization

  • Use Availity Essentials for real-time status updates
  • Set up automated notifications for request updates
  • Submit all documentation in single upload to avoid back-and-forth

Documentation Bundling

  • Create comprehensive evidence package upfront
  • Include peer-reviewed studies supporting gene therapy
  • Provide detailed treatment timeline and failure documentation
  • Attach cost-benefit analysis vs. standard treatments

Direct Specialty Routing

  • Request peer-to-peer review with BCBS medical director
  • Specify need for immunology/genetics specialist reviewer
  • Provide reviewer with published outcomes data from SR-TIGET

International Coverage Coordination

If you have supplemental international coverage, coordinate submissions:

  • Submit to primary BCBS plan first
  • Prepare secondary claims for travel coverage
  • Verify direct billing arrangements with SR-TIGET

Common Denial Reasons and Solutions

Denial Reason Solution Strategy Required Documentation
Experimental/Investigational Cite EMA approval, published outcomes EMA approval documents, peer-reviewed studies
No in-network alternative Document U.S. availability limitations Specialist letters, treatment center surveys
International exclusion Appeal based on medical necessity Evidence of unique treatment availability
Lack of medical necessity Strengthen clinical justification Genetic testing, treatment failures, prognosis
Incomplete documentation Resubmit with full package All required forms and clinical evidence

Getting Help with Your Appeal

Counterforce Health specializes in turning insurance denials into targeted, evidence-backed appeals for complex therapies like gene treatments. The platform helps patients and clinicians navigate prior authorization requirements by analyzing denial letters and drafting point-by-point rebuttals aligned to each plan's specific rules. For rare disease treatments requiring international care, Counterforce Health can help assemble the clinical evidence and procedural documentation needed to strengthen your case.

Virginia-Specific Resources

  • Bureau of Insurance Consumer Services: 1-877-310-6560
  • Managed Care Ombudsman: Same number, specialized HMO assistance
  • Virginia Poverty Law Center: Health assistance for complex appeals
From our advocates: We've seen ADA-SCID families succeed by emphasizing the one-time nature of gene therapy versus lifetime enzyme replacement costs, combined with detailed documentation of treatment failures. The key is presenting this as standard-of-care in Europe rather than experimental treatment, supported by published long-term outcome data.

FAQ

How long does BCBS Virginia PA take for gene therapy? Standard prior authorization takes 2-15 days, with expedited review available in 24-72 hours for urgent medical situations.

What if Strimvelis is considered experimental? Appeal by citing EMA approval, published safety/efficacy data, and medical necessity. Virginia external review can overturn experimental determinations.

Does BCBS cover treatment in Italy? Most standard plans don't cover elective international treatment. Check for GeoBlue or international coverage supplements, or pursue medical exception.

Can I get expedited review for ADA-SCID? Yes, if your physician certifies that delay would seriously jeopardize life or health. Document disease progression and urgency.

What happens if I'm denied twice? After internal appeals, pursue Virginia external review through the State Corporation Commission. Independent medical reviewers may overturn denials.

Do I need a U.S. second opinion? While not required, a supportive letter from a U.S. immunologist or geneticist strengthens your case by confirming limited domestic options.

How much will I pay out-of-pocket? Even with approval, expect significant cost-sharing for out-of-network international care. Explore manufacturer patient assistance and charitable foundations.

What if my employer plan is self-funded? Self-funded plans may opt into Virginia external review. If not, federal external review through HHS may be available.

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Insurance coverage decisions depend on individual plan terms and medical circumstances. Consult with your healthcare provider and insurance company for specific guidance.

Sources & Further Reading

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.